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Summary
Despite intensive investigation over the past 20 years, the specific role played by individual Gi protein family members in mediating
complex cellular effects is still largely unclear. Therefore, we investigated the role of specific Gi proteins in mediating somatostatin (SS)
effects in somatotroph cells. Because our previous data showed that SS receptor type 5 (SST5) carrying a spontaneous R240W mutation
in the third intracellular loop had a similar ability to inhibit intracellular cAMP levels to the wild-type protein but failed to mediate
inhibition of growth hormone (GH) release and cell proliferation, we used this model to check specific receptor–G-protein coupling by a
bioluminescent resonance energy transfer analysis. In HEK293 cells, wild-type SST5 stimulated the activation of Gai1–3 and GaoA, B,
whereas R240W SST5 maintained the ability to activate Gai1–3 and GaoB, but failed to activate the splicing variant GaoA. To investigate
the role of the selective deficit in GaoA coupling, we co-transfected human adenomatous somatotrophs with SST5 and a pertussis toxin
(PTX)-resistant GaoA (GaoA(PTX-r)) protein. In PTX-treated cells, GaoA(PTX-r) rescued the ability of the selective SST5 analog BIM23206
to inhibit extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation, GH secretion and intracellular cAMP levels. Moreover, we
demonstrated that silencing of GaoA completely abolished SST5-mediated inhibitory effects on GH secretion and ERK1/2
phosphorylation, but not on cAMP levels. In conclusion, by analysing the coupling specificity of human SST5 to individual Gai and Gao
subunits, we identified a crucial role for GaoA signalling in human pituitary cells.
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Introduction
The heterotrimeric guanine nucleotide binding proteins, known
as G proteins, composed of a, b and c subunits, are ubiquitous
and crucial signalling molecules which transduce signals from G-
protein-coupled receptors (GPCRs) to downstream intracellular
effectors. The distinct a subunits can be divided into four major
subfamilies represented by Gas, Gai, Gaq and Ga12. Proteins of
the Gi class, which includes several protein substrates for
pertussis toxin (PTX) ADP ribosylation such as Gi1-3 and
GoA,B, are involved in adenylyl cyclase inhibition, ion channel
modulation and phosphatase activation, but the specific role
played by individual G proteins in activating specific effector
molecules is still largely unclear.
The inhibitory effects of somatostatin (SS) on hormone
secretion and cell proliferation are mediated by a family of five
different GPCRs (SST1-5) coupled to multiple PTX-sensitive G
proteins (reviewed in Ben-Shlomo and Melmed, 2010). All five
subtypes are coupled to adenylyl cyclase inhibition and some
have also been found to reduce calcium entry by modulating L-
type Ca2+ and K+ channels (Yang and Chen, 2007), all these
events being involved in the inhibition of hormone release. The
anti-proliferative effects of SS are mainly mediated by SST2 and
5 by tyrosine phosphatase activation and inhibition of ERK1/2
phosphorylation, respectively (Lopez et al., 1997; Buscail et al.,
1995; Cordelier et al., 1997; Peverelli et al., 2009). The high
density of SSTs, in particular SST2 and 5, on human GH-
secreting adenomas has been used clinically to successfully treat
patients with acromegaly (Gueorguiev and Grossman, 2011), but
the specific G proteins and the molecular mechanisms involved
in intracellular signal transduction of these receptors have not
been completely clarified.
We have previously investigated human SST5 receptor
structural domains mediating intracellular signalling pathways
in the rat pituitary cell line GH3, focusing on the BBXXB domain
in the third intracellular loop and the DRY motif in the second
intracellular loop (Peverelli et al., 2008; Peverelli et al., 2009).
Our data indicated that residues D136 and R137 in the DRY
motif are critical for SST5 signalling since their substitution
abolished all intracellular responses. Conversely, mutations in the
BBXXB domain, and in particular the naturally occurring mutant
R240W identified in an acromegalic patient resistant to SS
analogues (Ballare` et al., 2001), resulted in a receptor with
retained ability to inhibit intracellular cAMP levels similarly to
the wild-type but failed to mediate the inhibition of GH release
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and cell proliferation. These data suggested that the R240W
mutation caused the loss of coupling with specific but yet
unidentified G proteins involved in the anti-proliferative and anti-
secretory effects of SST5.
In order to identify the Ga protein family members involved in
these effects, we employed a BRET biosensor that monitors the
conformational rearrangements between probes inserted in
heterotrimeric G protein complex (Gale´s et al., 2006; Busnelli
et al., 2012; Saulie`re et al., 2012). In particular, the GDP/GTP
exchange that occurs during receptor activation is translated into a
decrease in the energy transfer between the donor (Renilla
luciferase, Rluc, fused to a specific Ga subunit) and the acceptor
(a variant of green fluorescent protein, GFP10 fused to the Gc2
subunit). By this approach we found that R240W SST5 failed to
activate GaoA protein with respect to wild-type SST5, while the
activation of Gai1, i2, i3 and GoB was maintained. The role of GaoA
protein in the transduction of SST5 signalling was confirmed in
PTX pretreated human somatotrophs in which a PTX-resistant
GaoA was able to rescue the SST5 mediated inhibition of ERK1/2
activation and GH secretion. Accordingly, both effects were
abrogated in GaoA silenced cells. On the contrary, although GaoA
was able to mediate a reduction of cAMP levels, other G proteins
were involved in this effects, as demonstrated by persistence of
cAMP inhibition in GaoA silencing experiments.
By demonstrating the coupling specificity of human SST5 to
individual Gai and Gao subunits, our data revealed a crucial role
for GaoA signalling in human pituitary somatotrophs.
Results
G proteins activated by wild-type SST5
The BRET biosensor is schematically represented in Fig. 1A. The
bioluminescent energy transfer occurs between the energy donor
(Rluc) inserted within the Ga subunit amino acid sequence, and the
acceptor (GFP10) fused to the N-terminus of Gc2 subunit (Gale´s
et al., 2006). To investigate the specific ligand-induced G protein
activation by wild-type SST5, we co-transfected HEK293 with
wild-type SST5, Ga-RLuc, Gc2-GFP10 and complementary Gb1
subunit. In particular, we tested six different Ga-RLuc subunits
(Gai1, i2, i3, q, oA, oB) by transfecting the corresponding plasmids
(described in Saulie`re et al., 2012; Busnelli et al., 2012). A significant
(P,0.001 versus PBS treated cells) BRET signal ratio decrease was
obtained following wild-type SST5 activation by specific agonist
BIM23206 (100 nM) with the Gai1,2,3 and GaoA,B subunits, whereas
no decrease was observed with Gaq, as shown in Fig. 1B.
These data indicate that human SST5 activates all Gai
subtypes subunits including both isoforms of Gao, without
affecting Gaq. Although all experiments were performed using
similar expression levels of donor (RLuc) and acceptor (GFP10;
see Materials and Methods), the maximal amplitude of
BIM23206-promoted BRET signals detected with the different
Gai Gao donor probes do not necessarily reflect differences in
maximal coupling efficiency due to intrinsic differences in
intramolecular rearrangements in the single Ga-RLuc constructs
(Saulie`re et al., 2012). Therefore, in this biomolecular assay, the
maximal amplitude of BRET signal was not informative of how
efficiently a receptor is coupled to a single Ga subunit.
G proteins activated by R240W SST5
In previous studies we reported that R240W mutation did not
change receptor expression at the plasma membrane, nor its
binding profile or ability to inhibit intracellular cAMP levels,
while it prevented the ability to mediate the inhibition of GH
release and cell proliferation (Ballare` et al., 2001; Peverelli et al.,
2008; Peverelli et al., 2009). Efficient localization at the plasma
membrane was now further confirmed in HEK 293 cells
(supplementary material Fig. S1). As all these data suggest that
the R240W mutation causes a perturbation in the coupling with
specific G proteins mediating the anti-proliferative and anti-
secretory effects of SST5, we co-transfected HEK-293 cells with
R240W SST5, together with Ga-RLuc (Gai1, i2, i3, q, oA, oB), Gc2-
GFP10 and complementary Gb1. As observed for wild-type
SST5, BIM23206 activated R240W SST5/Gai1, i2, i3 and
GoB complexes, as indicated by the significant decrease in
BRET signal (P,0.001 versus PBS-treated cells; Fig. 1C).
Interestingly, no significant activation of GoA was detected.
It is worth noting that, compared to the wild type, the R240W
mutant displayed a reduction of the BRET signal for all the Ga
isoforms. This general reduction was not caused by different
transfection efficiency, as revealed by the very similar and
reproducible values of fluorescence for GFP10-Gc2
(25,4026108.4) and total luminescence for Ga-Rluc constructs
(mean 37,2696986.5 arbitrary units) in the different
experiments, suggesting that, in addition to the inability to
activate GoA, the mutant receptor showed a reduced capability to
reach G protein selective active conformations.
Fig. 1. BRET measurements of G protein activation following BIM23206
stimulation. (A) BRET was measured between Rluc (the donor, represented
as a circle) and GFP10 (the acceptor, represented as a star) introduced into the
a-helical domain of the indicated Ga subunits and the N-terminal domain of
Gc2, respectively. BIM23206-induced Ga activation leads to a
conformational rearrangement of the heterotrimeric G-protein complex that
corresponds to a decrease in BRET ratio. BRET was measured in HEK293
cells co-expressing wild-type SST5 (B) or R240W SST5 (C) together with
GFP10-Gc2, Gb1 and Rluc-tagged Ga subunits: ai1, ai2, ai3, aq, aoA, aoB.
The results shown here represent the differences in BRET signal after
BIM23206 (100 nM) or PBS stimulation, and are expressed as mean values6
s.d. One-way ANOVA by Dunnett’s test was used to determine the statistical
differences between SST5-agonist-promoted BRET in the presence of the
indicated Ga proteins and untreated controls (baseline) *P,0.01.
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GoA and GoB expression in adenomatous somatotrophs
Gi proteins are expressed ubiquitously, whereas Go proteins show
a more restricted expression pattern. In particular, no data are
available on the expression of the two isoforms of Go in
somatotrophs, that are well characterized targets of SST5-
mediated action. Therefore, before investigating the role of Go
isoforms in the pituitary, we performed preliminary experiments
by RT-PCR analysis on tissue samples obtained from human
somatotroph adenomas (n58). Our data showed that both GaoA
and GaoB transcripts were expressed in all the samples analysed
(supplementary material Fig. S2).
GaoA(PTX-r) restored the ability of SST5 to inhibit ERK1/2
phosphorylation in PTX-pretreated somatotrophs
The anti-proliferative effects of SS are mediated by SST5
through inhibition of ERK1/2. To investigate the role of GoA
protein in mediating SST5 signalling, we transfected cultured
somatotrophs from four human adenoma samples with SST5
receptor alone or together with mutated PTX-resistant GoA
(GaoA(PTX-r)). Transfected cells were incubated for 16 h with
100 ng/ml PTX, and finally stimulated in fresh medium with or
without the SST5 selective agonist BIM23206. Western blot
analysis (Fig. 2A) showed a significant reduction (5667%,
P,0.01 versus basal) in ERK1/2 phosphorylation by
BIM23206, that was abolished by the PTX-induced blockade of
all the endogenous PTX-sensitive G proteins (565%, P50.6
versus basal). When we co-transfected GaoA(PTX-r), the inhibitory
effect (5169%, P,0.01 versus basal) was maintained after PTX
treatment (6262%, P,0.01 versus basal and P,0.01 versus
corresponding SST5-transfected cells), suggesting that this G
protein was able to mediate the reduction in ERK1/2
phosphorylation. The rescue effect of GaoB(PTX-r) protein was
less pronounced (1664% of ERK1/2 inhibition after PTX
treatment, P,0.05).
GaoA(PTX-r) restored the ability of SST5 to inhibit GH
secretion in PTX pretreated somatotrophs
To further analyse the role of GoA on the biological responses
elicited by SST5 activation, we investigated the regulation of GH
release from cultured adenomatous somatotroph cells (n56). As
shown in Fig. 2B, the exposure of cells transfected with SST5 to
the specific agonist BIM23206 (10 nM) caused a slight but
significant reduction in basal GH release (16613% inhibition,
P,0.05 versus basal), while in PTX pretreated cells BIM23206
was ineffective. As observed for the inhibition of ERK1/2
phosphorylation, the expression of GaoA(PTX-r) restored the
ability of SST5 to reduce basal GH secretion (1364%, P,0.05
versus corresponding basal). On the contrary, GaoB (PTX-r) was
not able to rescue this effect.
GaoA silencing abolishes the inhibitory effects of SST5 on
ERK1/2 phosphorylation and GH secretion in
somatotrophs
In order to evaluate whether GaoA is essential for ERK1/2
phosphorylation and GH secretion inhibition in somatotrophs, we
used a specific siRNA selectively targeting this isoform. RT-PCR
analysis was performed to test the efficiency and the specificity
of silencing. As shown in Fig. 3A, after 72 h transfection with
GaoA siRNA, GaoA transcript was undetectable, whereas no
alterations of GaoB mRNA was observed. A negative control
siRNA, i.e. a non targeting sequence without significant
homology to the sequence of human transcripts, was used in all
experiments. To test ERK1/2 activation, cultured adenomatous
somatotrophs from three adenoma samples were transfected with
negative control or GaoA siRNA for 72 h and then stimulated
with BIM23206 for 10 min (Fig. 3B). As expected, the exposure
of cells transfected with negative control siRNA to BIM26203
resulted in a reduction in ERK1/2 phosphorylation (52610%
inhibition, P,0.05 versus basal). On the contrary, GaoA silencing
completely abolished the ability of BIM23206 to inhibit ERK1/2
phosphorylation, indicating that this isoform is required for
SST5-mediated inhibition of this proliferative pathway.
We next investigated by siRNA technique the role of GaoA
in mediating GH release inhibition (Fig. 3C). As expected,
stimulation of cells transfected with negative control siRNA with
Fig. 2. GaoA(PTX-r) restored the ability of BIM23206 to inhibit ERK1/2
phosphorylation and GH secretion in PTX-treated adenomatous
somatotroph cells. (A) A representative immunoblot of ERK1/2
phosphorylation demonstrating that the SST5-mediated reduction of ERK1/2
by BIM23206 (10 nM for 10 min) observed in SST5-transfected cells was
abolished after PTX treatment and restored in GaoA(PTX-r)-transfected cells.
The rescue effect of GaoB(PTX-r) protein was less pronounced. The graph
shows the quantification of phospho-ERK1/2 normalized to total ERK1/2
(mean values 6 s.d. from four independent experiments). *P,0.05,
**P,0.01 versus corresponding basal, §P,0.01 versus corresponding SST5-
transfected cells,
˚
P,0.05 versus BIM23206; t-test. (B) GaoA(PTX-r) restored
the ability of BIM23206 to inhibit GH secretion in PTX-treated adenomatous
somatotroph cells. Cells were transfected for 48 h with human wild-type
SST5, GaoA(PTX-r) or GaoB(PTX-r) and incubated for 3 h with fresh medium
containing BIM23206. In SST5-transfected cells, BIM23206 caused a slight
but significant reduction of basal GH release. After PTX pretreatment, no
significant effect of BIM23206 on GH release was observed, whereas
transfection with GaoA(PTX-r), but not GaoB(PTX-r), restored GH responsiveness
to BIM23206. *P,0.05 versus corresponding basal value; t-test.
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BIM23206 for 3 h reduced GH secretion in culture medium
(1869%, P,0.05 versus basal). This effect was completely lost
in GaoA-silenced cells, demonstrating the essential role of this
protein in mediating the anti-secretion effect of SST5.
Role of GaoA in SST5-mediated inhibition of intracellular
cAMP levels
Since little is known about the ability of Go to inhibit adenylyl
cyclase, we tested the ability of GaoA and GaoB to reduce
forskolin-stimulated intracellular cAMP levels, that reflects the
reduction in adenylyl cyclase activity in the presence of
phosphodiesterase inhibitors. Experiments were performed in
cultured cells from three GH-secreting adenomas (Fig. 4A). As
expected, BIM23206 (10 nM) inhibited forskolin-stimulated
cAMP accumulation in cells transfected with SST5 (2568%
inhibition, P,0.05), while this effect was abolished after PTX
pretreatment. Co-trasfection of SST5 and GaoA(PTX-r), but not
GaoB(PTX-r), rescued the ability of SST5 to inhibit forskolin-
stimulated intracellular cAMP levels (3565% inhibition in cell
transfected with GaoA(PTX-r) and pretreated with PTX, P,0.01).
To test whether other G proteins are involved in this effect, we
silenced GaoA protein in cultured cells from three GH-secreting
adenomas (Fig. 4B). We observed a dose-dependent reduction in
forskolin-stimulated intracellular cAMP levels both in negative
control and GaoA siRNA transfected cells (3066% and 4368%,
at 10 nM, respectively, P,0.05), demonstrating that GaoA is not
essential to inhibit adenylyl cyclase activity in pituitary
somatotrophs.
Discussion
This study identified the specific role played by different Gi protein
family members in mediating the inhibitory signals of SST5 in
human somatotroph cells. Previous studies on receptor–G-protein
Fig. 4. Role of Gao in SST5-mediated adenylyl cyclase inhibition.
(A) 48 h after transfection, cells were pre-incubated with IBMX for 30 min,
and subsequently with 1 mM forskolin with or without BIM23206 (10 nM) for
30 min. In cells transfected with SST5, the selective agonist BIM23206
(10 nM) inhibited forskolin-stimulated cAMP accumulation whereas this
effect was abolished after PTX pretreatment. Co-transfection of SST5 and
GaoA(PTX-r), but not GaoB(PTX-r), rescued the ability of SST5 to inhibit
forskolin-stimulated intracellular cAMP levels. *P,0.05, **P,0.01 versus
corresponding basal value; ˚P,0.05 versus BIM23206; t-test. (B) GaoA is not
required for SST5-mediated inhibition of forskolin-stimulated cAMP
accumulation. Cells were incubated with negative control siRNA or GaoA
siRNA for 72 h, pre-incubated with IBMX for 30 min and treated with
forskolin with or without BIM23206 (1 nM or 10 nM) for 30 min. The
inhibitory effect of BIM23206 on intracellular cAMP levels in adenomatous
somatotroph cells was maintained in GaoA-silenced cells. Values are means6
s.d. from three independent experiments, each determination was performed
five times. *P,0.05, **P,0.01 versus corresponding basal value; t-test.
Fig. 3. GaoA is required for the inhibitory effects of SST5 on ERK1/2
phosphorylation in pituitary somatotroph cells. (A) RT-PCR analysis was
performed after transfection with negative control siRNA or GaoA siRNA for
72 h. GaoA transcript was expressed in control cells and undetectable in
GaoA-silenced cells. No alterations of GaoB mRNA was observed. Negative
control siRNA (C-siRNA) is a non targeting sequence without significant
homology to the sequence of human transcripts. (B) Representative
immunoblot of ERK1/2 phosphorylation demonstrating that SST5-mediated
inhibition of ERK1/2 by BIM23206 (10 nM, 10 min) was present in C-siRNA
and abolished in GaoA-siRNA-transfected cells. The graph shows the
quantification of phospho-ERK1/2 normalized to total ERK1/2 (mean values
6 s.d. from three independent experiments). *P,0.05 versus corresponding
basal value; **P,0.01 versus corresponding basal value; t-test. (C) GaoA is
required for SST5-mediated inhibition of GH release. GaoA silencing
abolished the inhibitory effect of selective SST5 agonist BIM23206 on GH
secretion in adenomatous somatotroph cells. Cells were incubated with
negative control siRNA or GaoA siRNA for 72 h and treated with BIM23206
for 3 h. GH was measured in the culture medium. Values are means 6 s.d.
from three independent experiments; each determination was done in
triplicate. *P,0.05 versus corresponding basal value; t-test.
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complexes performed by co-immunoprecipitation found that
SSTs are coupled to different G proteins (Gai 1, 2, 3, Gao),
although the specific coupling between individual members of
the same G-protein family and different SST subtypes
expressed in the tissues analysed remained largely undefined
(Law et al., 1993; Brown and Schonbrunn, 1993; Gu and
Schonbrunn, 1997). In particular, no data are available on SST5
specific coupling.
First, by using a novel BRET biosensor, here we show that
SST5 activates Gai 1, 2, 3 and GaoA, B in living cells. Although the
role of Gi proteins in mediating adenylyl cyclase inhibition is
well established, few information are available on the role of Go
proteins in target tissues, such as somatotrophs. Our previous
results (Peverelli et al., 2009) suggested that cAMP-independent
mechanisms are involved in the regulation of GH secretion and
cell proliferation in a pituitary cell model, since SST5 third
intracellular loop mutants, such as the naturally occurring
R240W mutant, lost the ability to inhibit hormone secretion
and cell growth, though maintaining the ability to reduce
intracellular cAMP levels. By BRET experiments we now
demonstrated that this mutant displays a reduction of G protein
activation that, in the case of the GaoA, results in a complete loss
of activation, suggesting that this isoform might play an essential
role in SST5 signal transduction.
A single gene encodes for both Gao subunits, and its
alternative splicing produces two mRNA products, GaoA and
GaoB, which differ in the alternative use of the two final exons 7/
8 and 9/10, respectively, thus coding for proteins with different
C-terminal primary sequences (Hsu et al., 1990). The extreme C
terminus of the G alpha protein is one of the most important
domains involved both in the selectivity of activation by GPCRs
(Blahos et al., 1998; Sasamura et al., 2000), and in the
downstream activation of different effectors (Masters et al.,
1988). In agreement with data reported in literature, our results
suggest that the C-terminal regions of the two splice variants
GaoA and GaoB are differentially involved in SST5 binding and
activation of different effectors. Furthermore, our data
demonstrate that R240 in the third intracellular loop of SST5 is
critical for its coupling with GaoA but not with Gai(1–3) and GaoB,
supporting the view that different regions of GPCR are required
for different G protein interaction, as previously demonstrated for
other GPCRs (Wu et al., 1995; Beqollari et al., 2009).
In contrast to Gi proteins, which are expressed ubiquitously,
the expression of Go is restricted to the central and peripheral
nervous system, endocrine cells and cardiomyocytes. Although
our group has previously demonstrated by western blot that Go
proteins are expressed in significant amounts in human pituitary
tumours (Ballare´ et al., 1997), the expression of the two splicing
variants GaoA/B was not assessed. In this work, RT-PCR data on
tissue samples from human somatotroph adenomas showed that
both GaoA and GaoB transcripts are expressed in all the samples
analysed.
Second, to test the hypothesis that GaoA may play an essential
role in SST5 signal transduction in somatotrophs, that represents
a well characterized target of SS action, we transfected primary
cell cultures from somatotroph adenomas with GaoA(PTX-r), a
GaoA resistant to PTX, and we analysed the effects triggered by
SST5 after PTX treatment. By this approach we demonstrated
that the inhibition of ERK1/2 phosphorylation and GH secretion
was completely rescued by GaoA(PTX-r), suggesting its direct
involvement in the generation of SST5-mediated inhibitory
signals.
Third, although the employ of Gao(PTX-r) constructs
demonstrated that GoA is sufficient to mediate the inhibitory
effects of SST5 in the absence of other endogenous PTX-
sensitive G proteins, this experimental approach did not provide
any information about the possible involvement of other G
proteins in the same pathways. To address this issue, we
transfected somatotroph cells with a specific siRNA targeting
GaoA but not GaoB isoform. Our results showed that in the
absence of GaoA no inhibition of ERK1/2 phosphorylation and
GH secretion was induced by SST5 agonist, demonstrating that in
the absence of GaoA the other endogenous G proteins expressed
in somatotrophs are not able to transduce these signals.
The last two findings support previous data obtained in
different cell systems indicating that SST5 is associated with the
inhibition of ERK phosphorylation (Buscail et al., 1995;
Cordelier et al., 1997; Peverelli et al., 2009) and firstly
demonstrate that the generation of this anti-proliferative
pathway is dependent on receptor coupling with GaoA.
However, the involvement of GaoA in inhibiting ERK1/2 is
most likely a cell specific event, since it has been reported that in
other cell systems, such as CHO cells, Gao activates ERK1/2
phosphorylation via PKC-dependent mechanism (van Biesen
et al., 1996). Moreover, the first somatic mutation for GNAO1
(R243H), recently described in breast cancer (Kan et al., 2010),
renders the protein constitutively active and promotes NIH3T3
cells growth by increasing Src-dependent activation of STAT3
(Garcia-Marcos et al., 2011).
Although no direct effector for GaoA has been characterized to
date, it has been demonstrated that inactive form of Gao directly
interacts with Rap1GAP (GTPase activating protein for the small
GTPase Rap1) (Jordan et al., 1999). Activation of Gao would
release Rap1GAP, leading to the inhibition of Rap activity. We
hypothesize that this mechanism in somatotrophs would
negatively modulating signalling by Rap1, with a consequent
inhibition of B-Raf/MEK/ERK1/2. Further studies are needed to
investigate the molecular mechanisms and the effectors
downstream of GaoA in different cell systems.
Overall, our results suggest a crucial role for GoA in mediating
the anti-secretion effect of SST5. We previously demonstrated
that SST5 R240W mutant was not able to induce any inhibitory
effect on intracellular calcium levels and GH release, while it
retained the ability to inhibit cAMP accumulation, suggesting
that the absent inhibition of hormone release may be attributable
to the failure of this receptor to reduce calcium influx (Peverelli
et al., 2009). The present data indicate that the R240W mutant
receptor activates Gai but not GaoA, supporting the view that Go
proteins are involved in calcium influx reduction, resulting in
decreased hormone exocytosis, consistent with previous data
supporting a cAMP-independent and Go-mediated inhibition of
calcium channels by SS (Degtiar et al., 1997).
Finally, contradictory data are available in the literature about
the ability of Go to inhibit adenylyl cyclase (Kobayashi et al.,
1990; Wong et al., 1992). Our results first suggest that GaoA is
able to mediate inhibition of adenylyl cyclase activity in GH-
secreting adenoma cells after SST5 activation, but its role is not
essential for this effects, since it was maintained after GaoA
silencing. Therefore, other members of Gai/o family seems to be
involved in adenylyl cyclase activity inhibition. These results are
in agreement with our previous data demonstrating the ability of
Journal of Cell Science 126 (2)642
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R240W SST5 to mediate reduction of intracellular cAMP levels,
in the absence of GaoA activation (Peverelli et al., 2009).
In conclusion, a more complete understanding of the functional
properties of SST5 and how it activates target G proteins is of
extreme importance to future drug discovery. The present results
might provide a basis for identification of SSTs functional
selective ligands (Urban et al., 2007; Schonbrunn, 2008; Cescato
et al., 2010), effective in specifically couple with GaoA. Additional
studies are needed to investigate whether GaoA reduced expression
or genetic alterations might be associated with pituitary tumour
resistance to pharmacologic treatment with SS analogues.
Materials and Methods
Constructs
Human wild-type and R240W SST5 cDNAs were amplified starting from previous
constructs as template (Peverelli et al., 2008) and subcloned into multiple cloning
site of pRc/CMV expression vector (Invitrogen). The sequence of all constructs
was verified by dideoxynucleotide sequencing. Preliminary immunofluorescence
results confirmed that wild-type and R240W SST5 are correctly expressed and
targeted to the plasma membrane in HEK293 cells (data not shown), as we
previously showed in other cell types (Peverelli et al., 2008). The plasmids
encoding for wild-type and R240W SST5 fused to DsRed2 fluorescent protein
were previously described in Peverelli et al. (Peverelli et al., 2008).
All G protein subunits coding plasmids for BRET experiments (Galphaq-97-
Rluc, Galphai1-91-Rluc, Galphai2-91-Rluc, Galphai3-91-Rluc, GalphaoA-91-
Rluc8 or GalphaoB-91-Rluc8) were previously described (Busnelli et al., 2012;
Saulie`re et al., 2012). GaoA C351I (GaoA(PTX-r)) and GaoB C351I (GaoB(PTX-r))
plasmids were purchased from Missouri S&T cDNA Resource Center.
Fluorescence microscopy
HEK293 cells were transiently co-transfected with same amounts (7 mg) of SST5-
DsRed2 and R240W SST5-DsRed2 alone or with the same constructs used for
BRET experiments: Galphai1-91-Rluc (4 mg) or GalphaoA-91-Rluc8 (4 mg),
GFP10-Gc2 (5 mg) and Gb1 (4 mg). Forty-eight hours after transfection, the cells
were fixed with 4% paraformaldehyde for 20 min at room temperature, and
washed several times in PBS and once with H2O, and the glass coverslips were
mounted with MOWIOL. The cells were analysed using an LSM 510 META
confocal laser-scanning microscope (Zeiss, Jena, Germany) and the following filter
set: HeNe543, HFT 488/543 (dichroic) and emission filter LP560.
RT-PCR analysis of GaoA/B expression
RNA was extracted using standard methods (Trizol, Invitrogen, S.R.L., Italy) from
GH-secreting adenomas (n58) in order to verify the expression of GaoA/B, as well as
from cultured cells in silencing experiments. To examine the expression of GaoA and
GaoB transcripts, 3 mg of total RNA were reverse transcribed (Promega, Madison
WI, USA) and 5 ml of the cDNA was subjected to PCR using a common upstream
primer located in exon 3–4 (59-AGAAAGGCTGACGCCAAGAT-39) and two
specific downstream primers located in exon 7 (59-AGTCGAAGAGCATG-
AGAGAC-39) and 9 (59-TGGACGTGTCTGTGAACCAT-39), amplifying GaoA
or GaoB, respectively. The b-actin transcript was used as a control.
Cell cultures and transfection
HEK-293 cells were cultured in DMEM containing 10% fetal calf serum at 37 C˚ in
a humidified atmosphere of 95% air, 5% CO2. Transient transfections of G protein
subunits and SST5 were performed using polyethylenimine (PEI linear, MW
25000, Polysciences Europe GmbH, Eppelheim, Germany) according to the
instructions by the manufacturer.
Human pituitary cells were obtained from 12 GH secreting adenomas surgically
removed by the trans-sphenoidal route. The study was previously approved by the
local ethics committee. Informed consent was obtained from all subjects involved
in the study.
Tissues were enzymatically dissociated in DMEM containing 2 mg/ml
collagenase (Sigma-Aldrich, St Louis, MO) at 37 C˚ for 2 h, as previously
described (Lania et al., 2004). Transient transfections of SST5, GaoA and GaoB
were performed in cultured cells using JetPEI (Polyplus transfection, San Marcos,
CA) according protocols previously optimized in our lab (Peverelli et al., 2012).
Western blotting was performed in each experiment to control the expression level
of SST5 in transiently transfected cells.
GaoA silencing in pituitary adenoma cells
GaoA gene silencing was performed in GH-secreting pituitary adenoma cells using
specific custom siRNA and siPORT NeoFX transfection agent according to
manufacturer’s instructions (Ambion, Austin, TX, USA). In order to obtain the
best efficiency of silencing, three different siRNAs purchased from Ambion were
tested. Preliminary experiments to determine the optimal concentration of siRNAs
and the kinetics of silencing were performed. RT-PCR was performed to verify
that GaoA silencing does not affect GaoB transcript. A negative control siRNA, a
non targeting sequence without significant homology to the sequence of human
transcripts, was used in each experiment. GaoA silencing was verified by RT-PCR
analysis in each silencing experiment.
BRET assay
To detect the activation of the different Ga subunits by BRET experiments,
HEK293 cells were co-transfected with either wild-type or R240W SST5 and Gaq-
97-Rluc, Gai1-91-Rluc, Gai2-91-Rluc, Gai3-91-Rluc, GaoA-91-Rluc8, GaoB-91-
Rluc8 constructs in the presence of plasmids encoding for GFP10-Gc2 and Gb1.
To avoid possible variations in the BRET signal resulting from fluctuation in the
relative expression level of donors and acceptors, we set up transfection conditions
in which comparable protein expression levels were maintained constant and
similar values of total luminescence were obtained for all Ga-Rluc constructs. In
particular, for transfection we used a 20 mg mix of DNA containing: 4 mg Ga-
Rluc, 5 mg Gc2-GFP10, 4 mg Gb1 and 7 mg receptor. Forty-eight hours after
transfection, cells were washed twice, detached and resuspended with PBS MgCl2
0.5 mM at room temperature. They were then distributed in a white 96-well
microplate (100 mg of proteins per well; Optiplate, Perkin Elmer, Monza, Italy),
and incubated in the presence or absence of BIM23026 100 nM for 2 min before
substrate addition. The BRET between Rluc/Rluc8 and GFP10 was measured
immediately after the addition of the Rluc substrate coelenterazine 400a (5 mM),
using an Infinite F500 reader plate (Tecan, Milan, Italy) that allows the sequential
integration of light signals detected with two filter settings (Rluc/Rluc8 filter 370–
450 nm; GFP10 filter 510–540 nm). The data were recorded and the BRET signal
was calculated as the ratio between GFP10 emission and the light emitted by Rluc/
Rluc8. The changes in BRET induced by the ligand were expressed on graphs as
‘BIM23206-promoted BRET’ using the formula: ligand-promoted BRET 5
(emission GFP10 BIM23206/emission Rluc BIM23206) 2 (emission GFP10 PBS/
emission Rluc PBS).
Immunoblotting analysis of p42/44
Pituitary cells were transfected with wild-type or mutated SST5 for 48 h, incubated
with 100 ng/ml PTX (Sigma Aldrich, St Louis, MO) for 16 h in serum-starved
medium and then stimulated with 10% FBS with or without 10 nM BIM23206 for
10 min. In silencing experiments, cells were silenced for 72 h with GaoA siRNA or
negative control siRNA before stimulation with 10% FBS containing medium with
or without 10 nM BIM23206 for 10 min. As previously described (Peverelli et al.,
2009), cells were then lysed in lysis buffer in the presence of protease inhibitors.
Proteins were separated on SDS/polyacrylamide gels and transferred to a
nitrocellulose filter. To detect phosphorylated p42/44 proteins, 1:2000 dilution
of anti-phospho-p42/44 antibody (Cell Signaling, Danvers, MA) and an anti-rabbit
HRP-linked antibody were used. The presence of total p42/44 was analysed by
stripping and reprobing with anti-total p42/44 antibody (1:1000, Cell Signaling,
Danvers, MA). Chemiluminescence was detected using the ChemiDoc-IT Imaging
System (UVP, Upland, CA) and analysed using the image analysis program NIH
ImageJ.
GH release
GH-secreting adenoma cells were transfected for 48 h with SST5, GaoA(PTX-r) or
GaoB(PTX-r) or silenced for 72 h with GaoA siRNA or negative control siRNA and
then incubated for 3 h with fresh medium containing 10 nM BIM23206. Human
GH was measured in culture medium using specific immunoassays (Perkin Elmer,
Finland), according to the manufacturer’s instructions.
cAMP assay
GH-secreting adenoma cells were transfected with for 48 h with SST5, GaoA(PTX-r)
or GaoB(PTX-r) or silenced for 72 h with GaoA siRNA or negative control siRNA.
To quantify the inhibition of forskolin-induced cAMP accumulation, transfected
cells were pre-incubated with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) for
30 min, and subsequently with 1 mM forskolin with or without BIM23206 (1 nM
or 10 nM) for 30 min at 37 C˚. At the end of incubation, the medium was removed
and intracellular cAMP was measured. Cells were lysed and assayed by enzymatic
immunoassay (cAMP-Glo Assay, Promega, Madison, WI, USA) according to the
instruction of the manufacturer. Experiments were repeated at least three times and
each determination was performed five times.
Data analysis
The results are expressed as the means 6 s.d. All data were tested a priori for
normal distribution by using D’Agostino and Pearson omnibus normality test
(GraphPad Prism 5.0). A paired two-tailed Student’s t-test was used to detect the
significance between two series of data. P,0.05 was accepted as statistically
significant. One-way ANOVA by Dunnett’s test was used to determine the
statistical differences between SST5-agonist-promoted BRET in the presence of
the different Ga proteins and untreated controls.
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